SCHEMBL6500768

SCHEMBL6500768

C[C@H](NC(=O)OCc1ccccc1)[C@@H](O)C(Cl)c1cccc2ccccc12

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 6/20 0.56
ATM Q13315 1/20 0.45
ALDH1A1 P00352 1/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2C9 P11712 1/20 0.44
HPGD P15428 1/20 0.44
CYP2C19 P33261 1/20 0.44
HSD17B10 Q99714 1/20 0.44
TOP2A P11388 2/20 0.44
TOP2B Q02880 2/20 0.44
CTSL P07711 1/20 0.44
CTSS P25774 1/20 0.44
METAP2 P50579 1/20 0.43
METAP1 P53582 1/20 0.43
EPHX2 P34913 2/20 0.43
CTSK P43235 2/20 0.43
ELANE P08246 1/20 0.42
PLAU P00749 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6501321 1.00 CASP1 (0.56) CASP1ATMALDH1A1CYP1A2CYP3A4
SCHEMBL7141233 0.86 CASP1 (0.60) CASP1ATMALDH1A1CYP1A2CYP3A4
SCHEMBL7109176 0.83 CASP1 (0.54) CASP1ATMALDH1A1CYP1A2CYP3A4
SCHEMBL29207429 0.82 CASP1 (0.63) CASP1ATMTOP2ATOP2BMETAP2
SCHEMBL6487625 0.81 CASP1 (0.57) CASP1ATMALDH1A1CYP1A2CYP3A4
SCHEMBL18157218 0.78 ATM (0.57) ATMCTSLCTSSCTSKELANE
SCHEMBL2397435 0.76 CASP1 (0.62) CASP1CTSLCTSSCTSK
SCHEMBL13168669 0.76 CASP1 (0.56) CASP1ATMALDH1A1TOP2ATOP2B
SCHEMBL27615641 0.76 ATM (0.45) ATMALDH1A1CYP1A2CYP3A4CYP2C9
SCHEMBL6841165 0.75 CTSS (0.61) ATMCTSLCTSSCTSKELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6888012-B2 Reducing an alpha -haloketone compound by asymmetric hydrogen transfer in presence of a group 9 transition metal compound having a substituted or unsubstituted cyclopentadienyl group and an optically active diamine compound AJINOMOTO CO., INC. (JP) 2005-05-03 US disclosed
US-20040082820-A1 Hydrogen transfer reduction; useful as intermediate for production of pharmaceuticals/agricultural chemicals AJINOMOTO CO., INC. (JP) 2004-04-29 US disclosed
EP-1346972-A1 PROCESS FOR PRODUCING OPTICALLY ACTIVE HALOHYDRIN COMPOUND Ajinomoto Co., Inc. (JP) 2003-09-24 EP disclosed
EP-1345580-A1 COMPOSITION FOR OXIDATION DYEING OF KERATINOUS FIBRES COMPRISING A DIAMINO PYRAZOLE AND A CARBONYL COMPOUND L'OREAL (FR) 2003-09-24 EP disclosed
WO-2002051373-A1 COMPOSITION FOR OXIDATION DYEING OF KERATINOUS FIBRES COMPRISING A DIAMINO PYRAZOLE AND A CARBONYL COMPOUND L'OREAL (FR) 2002-07-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082820-A1 Hydrogen transfer reduction; useful as intermediate for production of pharmaceuticals/agricultural chemicals DHPS, HDHD5, HYPK CASP1 3411/4885ATM 2144/4885ALDH1A1 1488/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.